Compare GILT & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GILT | ATXS |
|---|---|---|
| Founded | 1987 | 2008 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 747.5M | 722.1M |
| IPO Year | 1993 | 2015 |
| Metric | GILT | ATXS |
|---|---|---|
| Price | $12.30 | $12.91 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 6 |
| Target Price | $16.00 | ★ $24.33 |
| AVG Volume (30 Days) | 543.1K | ★ 1.3M |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.22 | N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $392,826,000.00 | $706,000.00 |
| Revenue This Year | $49.48 | N/A |
| Revenue Next Year | $13.61 | N/A |
| P/E Ratio | $30.72 | ★ N/A |
| Revenue Growth | ★ 29.68 | N/A |
| 52 Week Low | $5.30 | $3.56 |
| 52 Week High | $15.24 | $13.29 |
| Indicator | GILT | ATXS |
|---|---|---|
| Relative Strength Index (RSI) | 50.27 | 63.64 |
| Support Level | $11.91 | $12.70 |
| Resistance Level | $13.08 | $13.29 |
| Average True Range (ATR) | 0.46 | 0.22 |
| MACD | 0.17 | -0.06 |
| Stochastic Oscillator | 59.90 | 61.31 |
Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs), and Transceivers. The company's solutions support multiple applications with a full portfolio of products to address key applications including broadband access, cellular backhaul, enterprise, in-flight connectivity, maritime, trains, defense, and public safety.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.